KP-10614
KP-10614 is a potent, orally active platelet aggregation inhibitor. KP-10614 inhibits platelet aggregation induced by ADP with IC50 of 1 nM. KP-10614 causes dose-dependent inhibition of ex vivo platelet aggregation in rats. KP-10614 shows antithrombotic effects in various thrombosis models. KP-10614 can be used for thrombotic diseases research.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 130273-99-3
- Formel: C23H32O4
- Molecular Weight:372.50
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Chemical Information
-
CAS. Nr. 130273-99-3
-
Molecular Weight 372.50
-
Formel C23H32O4
-
SMILES
CCC#CC[C@H](C)[C@H](O)/C=C/[C@@H]1[C@]2([H])[C@@](C[C@H]1O)([H])C=C(C2)/C=C\CCC(O)=O
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)